SHA:600056

5 stories mentioning SHA:600056Updated 15d ago

Every FINWIRES story that references SHA:600056, newest first.

What's the latest news on SHA:600056?

China Meheco Wins Performance Compensation Dispute Involving Subsidiary

China Meheco (SHA:600056) received a court-mandated enforcement payment from shareholder Tibet Tiansheng related to performance compensation involving subsidiary Henan General Pharmaceutical, according to a Wednesday filing with the Shanghai bourse.The drug company received 101.2 million yuan in principal and interest from Tibet Tiansheng, while Henan General received 5 million yuan directly from the shareholder, the filing said.Meheco offset about 16.9 million yuan of its own debt to Tibet Tiansheng, the filing said.Meheco filed a lawsuit against Tibet Tiansheng regarding a performance compensation dispute related to Henan General in October 2024. An intermediate court in Beijing ruled with finality in favor of Meheco following appeals by the shareholder.

SHA:600056

Asia44d ago

China Meheco Subsidiary Gets China Supplementary Drug Approval for Blood Clot Drug

China Meheco (SHA:600056) subsidiary Tianfang Pharmaceutical received supplementary drug application approval from China's National Medical Products Administration for its tranexamic acid tablets, according to a Tuesday filing with the Shanghai bourse.The drug is used to treat various types of bleeding due to fibrinolysis, the process of preventing problematic blood clot formation, the filing said.Sales of the drug reached 47.7 million yuan in the first quarter, according to market data cited by the filing.

SHA:600056

Treasury48d ago

Meheco Raises 1 Billion Yuan from Two Super Short Bond Tranches

China Meheco (SHA:600056) raised 1 billion yuan from two tranches of super short-term bonds, according to a Friday filing with the Shanghai bourse.The drug company issued 500 million yuan in 270-day bonds with an interest rate of 1.45%. Industrial and Commercial Bank of China (HKG:1398, SHA:601398) was the lead underwriter, while Bank of Beijing (SHA:601169) was the joint lead underwriter.Meheco also issued another tranche of 500 million yuan bonds with a term of 145 days and a rate of 1.42%. China CITIC Bank (HKG:0998, SHA:601998) was the lead underwriter while China Everbright Bank (HKG:6818, SHA:601818) was the joint lead underwriter.

SHA:600056

Asia51d ago

Meheco's Eight Drugs Recommended for China's Centralized Procurement List

China Meheco Group (SHA:600056) said eight of its drugs were proposed to be selected for the twelfth round of China's National Centralized Drug Procurement, according to a Shanghai bourse filing on Tuesday.The drugs, which were all produced by the company's subsidiaries, are betahistine hydrochloride tablets, vonoprazan fumarate tablets, vitamin B6 injection, sacubitril/valsartan sodium tablets, isavuconazole sulfate for injection, edoxaban tosylate tablets, carbazochrome sodium sulfonate injection and valacyclovir hydrochloride tablets.

SHA:600056

Asia98d ago

Meheco Says Diclofenac Sodium Tablets Pass Chinese Drug Regulator's Consistency Evaluation

China Meheco Group's (SHA:600056) unit, Tianfang Pharmaceutical, received approval from China's National Medical Products Administration for its supplemental drug application for diclofenac sodium enteric-coated tablets after passing the regulator's consistency evaluation, according to a Shanghai bourse filing on Thursday.The evaluation tested the drug's quality and efficacy.The drug is mainly used for the treatment of inflammatory and degenerative rheumatic diseases, various rheumatic pain and gout.

SHA:600056

Track with the FINWIRES app suite

FolioX

Track SHA:600056 in your portfolio

WheelAI

Analyze SHA:600056 options with the wheel strategy

StockInsider

See market sentiment on SHA:600056